Nina Beri
Overview
Explore the profile of Nina Beri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oberstein P, Dias Costa A, Kawaler E, Cardot-Ruffino V, Rahma O, Beri N, et al.
Cancer Immunol Res
. 2024 Jul;
12(9):1221-1235.
PMID: 38990554
Innate inflammation promotes tumor development, although the role of innate inflammatory cytokines in established human tumors is unclear. Herein, we report clinical and translational results from a phase Ib trial...
2.
Werba G, Weissinger D, Kawaler E, Zhao E, Kalfakakou D, Dhara S, et al.
Nat Commun
. 2023 Jul;
14(1):3912.
PMID: 37400453
No abstract available.
3.
Beri N
Immunotherapy
. 2023 Apr;
15(7):541-551.
PMID: 37096964
Cholangiocarcinoma is an epithelial malignancy originating in the biliary tracts and frequently recurs even with surgical resection. Unresectable disease has a 5-year overall survival of less than 10%. Given this...
4.
Werba G, Weissinger D, Kawaler E, Zhao E, Kalfakakou D, Dhara S, et al.
Nat Commun
. 2023 Feb;
14(1):797.
PMID: 36781852
The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC) is a complex ecosystem that drives tumor progression; however, in-depth single cell characterization of the PDAC TME and its role in...
5.
Everett J, Sanoba S, Jing X, Stender C, Schmitter M, Baptiste A, et al.
Cancer Med
. 2022 Jul;
12(3):2345-2355.
PMID: 35906821
Background: Genetic testing is recommended for all pancreatic ductal adenocarcinoma (PDAC) patients. Prior research demonstrates that multidisciplinary pancreatic cancer clinics (MDPCs) improve treatment- and survival-related outcomes for PDAC patients. However,...
6.
Beri N
Future Oncol
. 2022 Jan;
18(11):1391-1402.
PMID: 35081733
Intrahepatic cholangiocarcinoma, a malignancy of the intrahepatic bile ducts, is the second most common primary liver malignancy and has been rising in incidence over the past several decades. Given its...
7.
Beri N, Patrick-Miller L, Egleston B, Hall M, Domchek S, Daly M, et al.
Clin Genet
. 2018 Nov;
95(2):293-301.
PMID: 30417332
Telephone disclosure of cancer genetic test results is noninferior to in-person disclosure. However, how patients who prefer in-person communication of results differ from those who agree to telephone disclosure is...
8.
Peppercorn J, Houck K, Beri N, Villagra V, Wogu A, Lyman G, et al.
Breast Cancer Res Treat
. 2015 Sep;
153(3):659-67.
PMID: 26386956
Women living in rural areas of the U.S. face disparities in screening mammography and breast cancer outcomes. We sought to evaluate utilization of mammography, awareness of screening guidelines, and attitudes...
9.
Huffman K, Koves T, Hubal M, AbouAssi H, Beri N, Bateman L, et al.
Diabetologia
. 2014 Aug;
57(11):2282-95.
PMID: 25091629
Aims/hypothesis: Targeted metabolomic and transcriptomic approaches were used to evaluate the relationship between skeletal muscle metabolite signatures, gene expression profiles and clinical outcomes in response to various exercise training interventions....